Skip to content

Author

Milena Pantić

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Case report Open access Nov 2026

Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) are rare, aggressive hematologic malignancies for which allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option. Pemigatinib, a reversible FGFR1-3 inhibitor, has substantial activity in chronic phase but lower...

Tino Vollmer, Christoph Schell, Milena Pantić et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.